2020 Videos Archives

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

2025-06-11T10:40:13-07:00December 1st, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Watch video

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

2025-06-11T10:43:19-07:00November 16th, 2020|2020 Videos, Videos|

Watch video

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

2025-06-11T10:44:14-07:00November 16th, 2020|2020 Videos, Videos|

Watch video

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

2025-06-11T10:45:34-07:00June 14th, 2020|2020 Videos, Featured Videos, Videos|

Watch video

VIRTUAL EHA: Clonality analysis with NGS is the new frontier in MRD detection

2025-06-11T10:51:22-07:00June 14th, 2020|2020 Videos, Featured Videos, Videos|

Watch video

VIRTUAL EHA: Incorporating NGS Methods for Routine Clonality Assessment and Disease Monitoring of Lymphoid Malignancies

2025-06-11T10:52:18-07:00June 14th, 2020|2020 Videos, Featured Videos, Videos|

Watch video

Clinical Utility of NGS in Lymphoid Malignancies

2025-06-11T10:53:16-07:00February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

VIRTUAL EHA: Clonality analysis with NGS is the new frontier in MRD detection

VIRTUAL EHA: Incorporating NGS Methods for Routine Clonality Assessment and Disease Monitoring of Lymphoid Malignancies

Clinical Utility of NGS in Lymphoid Malignancies

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

VIRTUAL EHA: Clonality analysis with NGS is the new frontier in MRD detection

VIRTUAL EHA: Incorporating NGS Methods for Routine Clonality Assessment and Disease Monitoring of Lymphoid Malignancies

Clinical Utility of NGS in Lymphoid Malignancies

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.